secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0000950170-23-063326
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney Q3 net loss widens to $42M; cash runway into Q4 2025
--------------------------------------------------------------

- Net loss $42.0M for Q3 2023 vs $33.9M for Q3 2022, driven by higher R&D costs.
- Cash, equivalents and marketable securities $396.3M at Sep 30, down from $490.3M at Dec 31, 2022.
- R&D expenses $32.2M in Q3 2023 vs $21.1M in Q3 2022, up 53% on clinical trial and staffing costs.
- G&A expenses flat at $14.4M; equity-based compensation offset prior-year business combination costs.
- Cash expected to fund operations into Q4 2025; 235.4M ordinary shares outstanding at Sep 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017023063326/0000950170-23-063326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017023063326/prok-20231114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-063326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer